Patient Assistant Programs and Medicare Part D - Pharmaceutical Executive

ADVERTISEMENT

Patient Assistant Programs and Medicare Part D
About 2.5 million low-income seniors who participate in pharma's access programs are eligible for drug coverage under Medicare Part D. But the programs are out of alignment—and may leave some patients...


Pharmaceutical Executive



Make the Switch
With the medicare part d prescription drug benefit program in effect, pharmaceutical companies have to decide how to handle the estimated 2.5 million low-income seniors who have been part of their patient assistance programs (PAPs). In many cases, it no longer makes sense for drug companies to continue to allow Medicare-eligible patients into their PAPs when more comprehensive assistance through Part D is available and the government is absorbing the cost.

At the same time, the transition of Medicare-eligible seniors from PAPs to Part D coverage will be far from seamless. The new drug benefit doesn't align perfectly with existing PAPs, so many seniors on PAPs who had benefited from free or sharply reduced prices for their medicines are worse off on Part D plans.

Pharmaceutical companies must carefully decide what support they will offer to PAP members. Those decisions include whether Medicare enrollees should continue to be eligible for company-sponsored PAPS, how best to encourage them to sign up for Medicare, and how to ensure that patients who do switch coverage continue to receive the medicines they require.


Toolbox: Institutional Assistance Programs
However, the industry will take its next steps toward redefining PAPs in the Part D environment under strict government guidance and scrutiny. Already, the Office of Inspector General (OIG) has placed severe limitations on companies willing to offer Part D-enrolled patients additional assistance in affording their prescription drugs.

The Rub

Nearly one-third (2.5 million) of the estimated eight million Americans currently enrolled in PAPs are over age 65 and are eligible to participate in the government's drug benefit program, available to all seniors and disabled individuals who qualify for Medicare, regardless of financial status. Historically, Medicare has covered hospital stays and in-patient medications; patients had to pay for medications out of pocket or enroll in a prescription drug plan to obtain their routine medications. To help those patients who could not afford their drugs, companies created PAPs, which offered free or reduced-priced therapies to qualified low-income patients, as determined by the manufacturer providing the program. The first PAPs were established more than 25 years ago, by such companies as Astra and Hoechst-Roussell. Today, PAPs are an industry standard, with companies' programs distributing $4 billion worth of drugs to needy patients in 2004, according to PhRMA.


Part D Poverty Split
The new Medicare Part D program, implemented through private health insurance companies, adds outpatient medications to the list of services for which Medicare pays. Although it's up to the insurance companies exactly what premiums are required and which drugs their programs will cover, the government has set guidelines for the plans relative to the categories and number of drugs that must be available in each category. Just like payers outside the Medicare realm, it is clear that many plans favor lower-priced generics over more expensive brand-name drugs.

The Medicare Part D program is truly beneficial for impoverished patients who live at the federal poverty level (FPL)—$9,570 for an individual, $12,830 for a two-member household—or up to 150 percent over the FPL, if they qualify for the low-income subsidy. Those patients will receive their medication with a very modest out-of-pocket cost, a nominal co-pay of $1 to $3, and pay no monthly premium.


ADVERTISEMENT

blog comments powered by Disqus
UPCOMING CONFERENCES

Serialization Summit
San Diego, CA
Feb. 27-28, 2014



Advances in Aseptic Processing
San Diego, CA
Mar. 10-12, 2014



ClinTech 2014
Cambridge, MA
Mar. 11-13 2014


Investigator-Initiated and
Sponsored Research (IISR)

Philadelphia, PA
Mar. 19-20 2014

See All Conferences >>

Source: Pharmaceutical Executive,
Click here